Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717632 | 0.91 | POLB (0.41) | KDM4EPOLBHINT1TAAR1HPRT1 | |
| SCHEMBL718291 | 0.86 | POLB (0.48) | POLBHINT1TAAR1STING1PDE3B | |
| SCHEMBL888190 | 0.82 | POLB (0.43) | KDM4EPOLBHINT1HPRT1STING1 | |
| SCHEMBL21538191 | 0.80 | POLB (0.48) | KDM4EPOLBHINT1HPRT1FUT5 | |
| SCHEMBL8003285 | 0.78 | POLB (0.51) | POLBHINT1TAAR1STING1PDE3B | |
| SCHEMBL15953158 | 0.76 | POLB (0.50) | POLBHINT1TAAR1HPRT1STING1 | |
| SCHEMBL715688 | 0.74 | P2RX3 (0.39) | POLBSTING1 | |
| SCHEMBL16459760 | 0.74 | POLB (0.41) | KDM4EPOLBHINT1HPRT1STING1 | |
| SCHEMBL14985927 | 0.73 | KDM4E (0.63) | KDM4EPOLB | |
| SCHEMBL18671307 | 0.73 | KDM4E (0.63) | KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11390858-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | QIAGEN SCIENCES, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10961574-B2 | Methods and compositions for incorporating nucleotides | QIAGEN SCIENCES, LLC (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210009969-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10774316-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10760063-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3699283-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYSTHESIS | Molecular Assemblies Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200190490-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-20200190491-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-20200071755-A1 | Methods and Compositions for Incorporating Nucleotides | IsoPlexis Corporation | 2020-03-05 | — | — | US | disclosed |
| US-20200040391-A1 | Methods and Compositions for Incorporating Nucleotides | IsoPlexis Corporation | 2020-02-06 | — | — | US | disclosed |
| US-10174066-B2 | Methods and compositions for incorporating nucleotides | QIAGEN WALTHAM, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10059929-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2018-08-28 | — | — | US | disclosed |
| US-9909174-B2 | Methods and compositions for incorporating nucleotides | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170211141-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | IsoPlexis Corporation | 2017-07-27 | — | — | US | disclosed |
| US-9322050-B2 | Hydroxymethyl linkers for labeling nucleotides | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160108382-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies, Inc. | 2016-04-21 | — | — | US | disclosed |
| US-20120052489-A1 | METHODS AND COMPOSITIONS FOR SEQUENCING NUCLEIC ACIDS USING CHARGE | INTELLIGENT BIO-SYSTEMS, INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110124054-A1 | Methods And Compositions For Inhibiting Undesired Cleaving Of Labels | INTELLIGENT BIO-SYSTEMS, INC. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040391-A1 | Methods and Compositions for Incorporating Nucleotides | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
| US-10174066-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
| US-10961574-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
| US-20200071755-A1 | Methods and Compositions for Incorporating Nucleotides | NT5C2, NOP2, NT5C3B | KDM4E 4166/4885POLB 44/4885HINT1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.